AbbVie reported FY 2025 worldwide net revenues of USD 61.16 billion (+8.6%), operating earnings of USD 15.1 billion, diluted earnings per share of USD 2.36, and cash flows from operations of USD 19.03 billion. Gross margin was USD 42.96 billion (70% of net revenues), while SG&A expenses were USD 14.01 billion and R&D expenses were USD 9.1 billion. Key product performance in FY 2025 included Skyrizi net revenues of USD 17.56 billion (+49.9%), Rinvoq USD 8.3 billion (+39.1%), and Humira USD 4.54 billion (down 49.5% due to biosimilar competition). Other notable products included Vraylar USD 3.62 billion (+10.8%), Botox Therapeutic USD 3.77 billion (+14.8%), Botox Cosmetic USD 2.6 billion (down 4.3%), and Venclexta USD 2.79 billion (+8.1%). AbbVie also cited costs in FY 2025 including USD 7.4 billion of intangible amortization, USD 6.5 billion from changes in fair value of contingent consideration liabilities, USD 847 million of intangible impairment, and USD 276 million of acquisition and integration expenses. Period highlights included U.S. FDA approvals for Rinvoq in giant cell arteritis and Emrelis (accelerated approval in NSCLC), an NDA submission for tavapadon in Parkinson’s disease, and a BLA submission for TrenibotE in glabellar lines. AbbVie said it settled U.S. litigation with generic challengers to Rinvoq, with no generic entry expected before April 2037 (assuming pediatric exclusivity). The company also announced a CEO-chair transition, with Robert A. Michael set to succeed Richard A. Gonzalez as chairman effective July 1, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001551152-26-000008), on February 20, 2026, and is solely responsible for the information contained therein.